All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lymphoma Hub

Lymphoma Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-11-03T10:56:04.000Z

ACR Convergence 2023 abstracts: What’s hot in systemic lupus erythematosus and lupus nephritis?

By Haimanti Mandal
Nov 3, 2023
Share:

Bookmark this article

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in lupus.

 

Systemic lupus erythematosus

0597

Efficacy of anifrolumab in systemic lupus erythematosus by overall and organ-specific SLEDAI-2K improvements: Results from the randomized, placebo-controlled phase 3 long-term extension study

0608

Efficacy of cenerimod in patients with high IFN-1 gene expression signature and high anti-dsDNA antibody levels: Post-hoc analysis from a phase 2 study

1489

Treatment with upadacitinib in patients with systemic lupus erythematosus results in the inhibition of B-cell–related biomarkers: Analysis of the M19-130 (SLEek) phase 2 study

2328

Deucravacitinib, an oral, allosteric, tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus: Patient-reported outcomes in a phase 2 trial

2487

Phase 2 safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; Anti-BAFFR mAb) administered monthly over 28 Weeks in patients with systemic lupus erythematosus (SLE) of moderate-to-severe activity

2488

Efficacy and safety of ABBV-599 high dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: A phase 2, double-blind, placebo-controlled trial

L13

An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T Cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: Preliminary results

 

Lupus nephritis

0595

Renal involvement in patients with systemic lupus erythematosus treated with anifrolumab compared with placebo over a 4-year period

0782

Comparison of dual-immunosuppressive therapy with a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis in the ALMS and AURORA 1 studies

0784

Kidney-related outcomes and steroid-sparing effects in patients with active lupus nephritis treated with obinutuzumab: A post hoc analysis of a phase 2 trial

ACR Convergence 2023 Abstracts

To download this document, click below.

Download here

More about...
ACR Convergence 2023Lupus nephritisSystemic lupus erythematosus

Related articles

Add bookmark

Editorial theme | Impact of SLE and LN on patients’ QoL and body image

We examine the impact of lupus nephritis and systemic lupus erythematosus on quality of life and body image disturbance in this editorial theme article.

Feb 3, 2023
Add bookmark

Editorial theme | Impact of SLE and LN on patients’ QoL and body image

We examine the impact of lupus nephritis and systemic lupus erythematosus on quality of life and body image disturbance in this...

Feb 3, 2023
Add bookmark

Zetomipzomib, a first-in-class immunoproteasome inhibitor, for the treatment of SLE and LN

Zetomipzomib, a first-in-class immunoproteasome inhibitor, was evaluated for safety and exploratory efficacy in patients with SLE and concurrent LN in the...

Dec 6, 2022
Add bookmark

Zetomipzomib, a first-in-class immunoproteasome inhibitor, for the treatment of SLE and LN

Zetomipzomib, a first-in-class immunoproteasome inhibitor, was evaluated for safety and exploratory efficacy...

Dec 6, 2022

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox